301 results about "New medications" patented technology

The invention discloses a Chinese herbal medicine knowledge graph construction method and system, and the method comprises the steps: collecting structured data and unstructured data, and generating a drug property and pharmacology data table; extracting property and flavor channel tropism attributes of the medicinal materials, generating a medicinal property triple and a pharmacological triple, and establishing preliminary cross-domain association; defining logical constraints and compatibility rules of nature and flavor channel tropism, and constructing a causal reasoning chain; performing spatial semantic mapping on the channel tropism attributes and the pharmacological entities to generate a dynamic cross-layer mapping relationship; using an attribute graph database to store node types and edge types, and constructing a hybrid index; new data streams are collected in real time, the atlas is updated, and an intelligent decision-making interface and a visual interaction platform are provided. Through multi-source fusion, dynamic association, efficient storage and closed-loop optimization, the problems of semantic segmentation, update lag and low retrieval efficiency in traditional Chinese medicine digitization are solved, and scientific and real-time technical support is provided for traditional Chinese medicine modernization research, accurate medication and new medicine research and development.

The invention relates to the technical field of extraction and separation of compounds in traditional Chinese medicinal materials, in particular to a method for simultaneously separating and purifying three pentacyclic triterpenoids from a tripterygium hypoglaucum root medicinal material. Three pentacyclic triterpenoid monomers are obtained through the steps of smashing, reflux extraction, normal-phase silica gel chromatography, reversed-phase high-pressure column chromatography, recrystallization and the like, the method is high in extraction efficiency and small in reagent dosage, the three pentacyclic triterpenoid compounds can be obtained at the same time, and the obtained compounds are high in purity and yield, have high social and economic value and are suitable for industrial production. The purity of the obtained plasmin, tripterine and demethylzeylasteral is high, and a foundation is laid for the preparation and production of reference substances of triterpenoid components in the roots of pyracantha fortunei, the subsequent pharmacological activity and the development of new immune drugs.

The invention discloses an alpha nuclide drug in-vitro cellular response prediction method and system based on multi-module mathematical modeling and a medium, and the method comprises the steps: constructing a basic parameter input module, a pharmacokinetic prediction module, a cell absorbed dose calculation module and a biological effect prediction module which are connected in sequence; a three-compartment dynamical model and a micro-dose learning point kernel convolution and DNA damage repair dynamical model are integrated, and full-chain and quantitative simulation from drug distribution, microscopic energy deposition to cell survival is achieved. The method overcomes the defects that an existing empirical model cannot accurately reflect the high LET characteristic of alpha particles, neglects the bystander effect and repair dynamics and the like, and the prediction precision is remarkably improved. According to the method, the curative effects of different drugs, cell lines and dosage schemes can be quickly simulated on a computer, the research and development cost and period are greatly reduced, and an efficient theoretical tool is provided for new drug screening and dosage optimization.

The invention discloses a computer-aided drug screening method, system or device based on FBXO2 and PKM2. The invention provides a brand-new method, system or equipment for screening oral squamous cell carcinoma treatment drugs based on FBXO2 and PKM2, provides a tool for new drug development and clinical application for treatment of oral squamous cell carcinoma, and has a wide application prospect.

The invention relates to the technical field of disease animal models, in particular to a construction method, an evaluation method and application of a bipolar affective disorder liver stagnation and spleen deficiency syndrome combined animal model. According to the method, a liver depression and spleen deficiency syndrome modeling method is adopted for model construction, evaluation indexes are formulated by combining manic and depression behavior expressions of mice and innovatively combining typical expressions of liver depression and spleen deficiency, a liver depression and spleen deficiency syndrome animal model evaluation method is explored, and a thought is provided for achieving standardization and normalization of liver depression and spleen deficiency syndrome model evaluation. The modeling method is simple and economical, provides an experimental animal model for syndrome differentiation treatment of diseases, particularly provides a corresponding animal model for traditional Chinese medicine syndrome differentiation treatment and new drug pharmacological experiments, accelerates the progress of traditional Chinese medicine disease syndrome research and new drug development, provides technical service for drug evaluation, and has great application value.

The invention relates to the technical field of biological medicine, and discloses an application of an Aspisin small-molecule inhibitor in preparation of a medicine for preventing and / or treating diabetic nephropathy, and the Aspisin small-molecule inhibitor comprises ganoderic acid DM. The inhibitor ganoderic acid DM targeting Aspisin is screened from a bioactive compound library by combining high-throughput virtual drug screening with biological activity screening, it is found that ganoderic acid DM can be specifically combined with Aspisin and shows high affinity, and it is expected that an experimental basis is provided for clinical treatment and prevention of DKD and new drug research and development.

The invention relates to a construction method of an atopic dermatitis mouse model. The method sequentially comprises the following steps: screening mice, feeding the mice in an SPF (specific pathogen free)-level animal house by adopting an illumination and darkness alternating period, and freely taking standard feed and drinking water; after the animals adapt to the environment, the animals are divided into a model group and a control group, and the control group is only subjected to first sensitization treatment; the model group is subjected to first-time sensitization treatment and maintenance treatment, the interval between the first-time sensitization treatment and the maintenance treatment is 4 days, and the maintenance treatment is performed for three times per week and is totally 16 days continuously. According to the method disclosed by the invention, the mouse model which is highly similar to human atopic dermatitis in immunology, pathology and molecular level is successfully established, the limitations of poor repeatability, incomplete pathological characteristics, single immunoreaction type and the like of the existing model are overcome, and an effective experimental platform is provided for disease research and new drug development.

This invention relates to the application of β-sitosterol glycoside in the preparation of products for treating lung cancer. This invention creatively provides a new use for the active monomer β-sitosterol glycoside, demonstrating that β-sitosterol glycoside can significantly inhibit the migration ability of lung cancer cells at doses without cell proliferation inhibitors, clarifying the specificity of its anti-metastatic effect, and laying the foundation for further new drug development of this monomer component. Through an in vivo mouse lung metastasis model, this invention demonstrates that β-sitosterol glycoside effectively inhibits the formation of lung metastases while exhibiting no significant toxic side effects in experimental animals, demonstrating high safety, and providing a new candidate molecule for the development of low-toxicity, highly effective anti-lung cancer metastasis drugs.

The invention discloses a compound of a Galectin-3 and EGFR (Epidermal Growth Factor Receptor) double-target inhibitor in the technical field of biological medicines, and the compound disclosed by the invention not only shows a relatively strong Galectin-3 and EGFR binding effect, but also has certain in-vitro anti-hepatic fibrosis activity, and can be applied to Galectin-3 and EGFR target related tumor diseases. As a double-target anti-hepatic fibrosis candidate compound based on Galectin-3 and EGFR, which is reported for the first time, the compound has further values of research and development and research of original new drugs based on double targets of Galectin-3 and EGFR.

The application discloses a preparation method of an abacavir metabolite, and belongs to the field of drug metabolite synthesis. The whole process is reasonable in design, strong in operability, and has high implementation value and social and economic benefits. The method uses compound I as a starting material, and synthesizes the abacavir metabolite through two-step reactions. The optimal synthesis step and reaction condition are screened through experiments. The abacavir metabolite synthesized by the method has a liquid-phase purity of 98.2% or above and a chiral purity of 99.9% or above, provides a test sample for abacavir research, and has important research reference value in clinical pharmacokinetic research and new drug research and development.

The present application belongs to the technical field of artificial intelligence assisted drug screening, and particularly relates to a method for screening active molecules against carbapenem-resistant enterobacteriaceae based on a LightGBM algorithm, a medium and an apparatus. The method constructs a LightGBM integrated learning framework, fuses ADME rules optimized for the outer membrane barrier characteristics of gram-negative bacteria and multi-target molecule docking verification, effectively solves the problem of data imbalance caused by the scarcity of active samples and the huge compound library, and significantly improves the hit rate of screening. The present application also provides a computer readable storage medium and an electronic device. By storing and executing the above program, the present application can quickly and standardizedly identify anti-CRE candidate molecules from a large number of compounds, greatly reducing the computing power cost and time cycle of new drug research and development. The present application is designed to overcome the bottleneck of gram-negative bacterial outer membrane permeation, and provides an efficient, accurate and intelligent screening tool for combating CRE super-bacterial infections.

The application discloses a kind of trichoderma fermentation processing indigo blue method, the product obtained and application.The method includes: preparation trichoderma seed liquid;After primary indigo blue sterilization, access seed liquid, fermentation 5-9 days under 25-30 DEG C, 120-180 rpm, avoid light, obtain secondary processing indigo blue.The application first utilizes trichoderma to carry out biological transformation to indigo blue, can significantly improve the content of its key anti-tumor component indigo carmine with specificity, and the increase is more than 150%.In vitro anti-tumor experiment shows that the inhibitory activity of secondary processing indigo blue prepared by the application to human leukemia K562 cells and human colon adenocarcinoma cell SW480 cell is significantly better than ordinary indigo blue.The product of the application can be used for preparing medicine for preventing and / or treating leukemia, colon adenocarcinoma, process controllable, suitable for industrialized production, and provides a new way for developing efficient indigo blue anticancer new drug.

The invention discloses a method for constructing a pressed butterfly mycin glycoside gene engineering strain by using glycosyl transferase and application of the pressed butterfly mycin glycoside gene engineering strain. A strong promoter kasOp * is introduced to the upstream of a glucoside transferase gene pie28 of Streptomyces psammoticus SCSIO NS126, the nucleotide sequence of the strong promoter kasOp * is as shown in SEQ ID NO. 1, and the nucleotide sequence of the glucoside transferase pie28 is as shown in SEQ ID NO. 2. The invention also discloses a preparation method of the Streptomyces psammoticus SCSIO NS126, and the preparation method of the Streptomyces psammoticus SCSIO NS126 comprises the following steps of: introducing the strong promoter kasOp * into the upstream of the glucoside transferase gene pie28. The streptomyces gene engineering strain Streptomyces sp. SK-kas28 constructed by the invention can efficiently express the chalcone glycoside, is widely applied to fermentation production of the chalcone glycoside, and is used for research and development of new drugs for treating kidney diseases and the like.

The application discloses use of LncRNA00_178, miR-466b-3p and Gucy1b1 as acute lung injury markers or drug targets, and belongs to the technical field of biomarkers and drug targets. LncRNA00_178 can be used as a biomarker for screening or diagnosing acute lung injury, a miR-466b-3p down-regulator can be used to prepare a pharmaceutical composition for preventing and treating acute lung injury, and Gucy1b1 can be used as a drug target to prepare a drug for preventing and / or treating acute lung injury. The application has the beneficial effects that the application proposes that LncRNA00_178 and miR-466b-3p, and miR-466b-3p and Gucy1b1 have a target binding relationship. LncRNA00_178 can be used as a biomarker for screening or diagnosing acute lung injury, the silence of miR-466b-3p inhibits LPS-induced apoptosis of alveolar epithelial cells, and Gucy1b1 can be used as a drug target to prepare a drug for preventing and / or treating acute lung injury. The data provide new insights for the treatment mechanism of ALI and the identification of specific targets, and provide a new idea for the research and development of new drugs for acute lung injury, and have a wide application prospect.

The present invention relates to a pharmaceutical composition for preventing or treating coronavirus disease 2019, and more specifically to a pharmaceutical composition for preventing or treating coronavirus disease 2019 found by drug repositioning technology using drug virtual screening technology. The pharmaceutical composition for preventing or treating coronavirus disease 2019 according to the present invention is a composition obtained by finding new uses for drugs, which have already been proven effective, for preventing or treating coronavirus disease 2019 by drug repositioning technology. The pharmaceutical composition is useful because it has significantly lower side effects than new drugs and can be rapidly applied to clinical practice.

The invention belongs to the field of biological medicine, and particularly relates to application of an active component based on a radish seed extract as an angiotensin converting enzyme inhibitor. The active ingredient is sinapine (sinapine) or nasturtoside (Gluconatutin), and the active ingredient is one or more than one of the active ingredients. According to the invention, affinity ultrafiltration is combined with a UPLC-Orbitrap-MS method, potential inhibitors are rapidly screened and identified on line from radish seeds, the affinity of active compounds and ACE is researched by combining molecular docking through ACE activity inhibition experiments, and finally two potential ACE inhibitors, namely sinapine and nasturtoside, are determined by combining an affinity ultrafiltration RBA value, IC50 and a binding force of molecular docking. And further research is carried out after screening, so that the research range is greatly reduced, the time of new drug discovery and research and development processes is saved, and the screening cost and risk are reduced.

The invention provides a construction method and application of a humanized MECP2 gene mouse model, and relates to the field of gene engineering. The model animal with the humanized hMECP2 gene is successfully prepared, the humanized hMECP2 protein can be normally expressed in the body of the model, and the model can be used for MECP2 gene function research and screening and evaluation of human MECP2 targeted drugs and therapies. The animal model prepared by the invention can be used for rapidly establishing more different MECP2 mutation humanized disease mouse models, and is applied to drug screening, drug effect research, related nervous system disease and tumor treatment and the like aiming at human MECP2 target sites, so that the research and development process of new drugs is accelerated, the time and the cost are saved, and the drug development risk is reduced. And a powerful tool is provided for researching the functions of the MECP2 protein and screening drugs.

The invention relates to the technical field of traditional Chinese medicine extraction and separation, in particular to two alkaloid compounds in portulaca oleracea and an extraction and separation method and application thereof. The molecular formulas of the two kinds of alkaloid compounds are both C27H33NO15, and the two kinds of alkaloid compounds are respectively named as oleraclamie K and oleraclamie L. The invention further discloses a preparation method of the oleraclamie. According to the method, water extraction, ODS column chromatography, Sephadex LH-20, a high performance liquid chromatograph and the like are adopted for separation, purification and preparation, the compounds oleraclamie K and oleraclamie L are successfully extracted and separated out, the method is simple, convenient and rapid, the extraction and separation process mainly adopts a water extraction process, the method is environmentally friendly, the purity of the compounds separated through the method is high and larger than 90%, and the method is suitable for industrial production. In addition, researches show that the two compounds have anti-inflammatory effects, so that the alkaloid compound and the salt and the derivative thereof can be used as synthesis primers of other compounds and raw materials for new drug development and pharmacological activity research, and can also be used for preparing anti-inflammatory drugs.

A drug complex may include a target recognition molecule bonded to a copolymer X including structural units of (A), (B), and (C):R1, R2, and R3 being independently H or C1-3 alkyl, R4 being C1-3 alkyl, R5 being H, C1-18 alkyl, 3- to 8-membered cycloalkyl optionally being substituted, adamantyl, C6-18 aryl optionally being substituted, or 5- to 10-membered heteroaryl group optionally being substituted, X1, X2, and X3 being independent O, S, or N—R7, R6 being H, leaving group, or linker, R7 being H or C1-3 alkyl group, m being 1 to 100, and n being 0 to 3.

The present application relates to a kind of saponins HZ extracted from shi medicine twelve hours and its preparation method and application.Twelve hours saponins HZ is prepared using the following method: with shi medicine twelve hours as raw material, using impregnation extraction, extraction, microporous resin MCI column chromatography separation to obtain extract Fr.B4, extract Fr.B4 is purified by Sephadex LH-20, obtain FrB4-1~FrB4-6 6 components, component FrB4-4 is separated by semi-preparative high performance liquid chromatography (CH3CN:H2O=30:70, 3.0mL / min) to obtain twelve hours saponins HZ.Twelve hours saponins HZ has significant effect in the treatment of ulcerative colitis, and can be further used for developing safe, effective, controllable traditional Chinese medicine anti-inflammatory, ulcerative colitis new drug.

The present invention relates to an industrially advantageous process for the preparation of pyridazinone derivative. More specifically, the present invention relates to an efficient process which is operationally simple and suitable for industrial application and will eliminate or limit the presence of impurities in the pyridazinone derivative, an investigational new drug.

This invention discloses a heterozygous sesquiterpene tricyclic epoxy compound derived from the strain *Arthrum oligosporum*, its preparation method, and its applications, belonging to the field of natural product chemistry. This invention provides a heterozygous sesquiterpene tricyclic epoxy compound derived from *Arthrum oligosporum* (… A.oligospora ) AOL_ s00210g57 Anthrobotrisin D, a novel heterozygous sesquiterpene tricyclic epoxy compound from a gene knockout strain, has been shown in vitro to possess excellent anti-inflammatory activity, significantly inhibiting lipopolysaccharide-induced inflammatory responses in mouse microglia. It exhibits a clear dose-dependent inhibitory trend at multiple levels, including NO release, protein and mRNA expression of inflammatory factors (TNF-α, IL-1β, IL-6), and iNOS protein and mRNA expression. Furthermore, at a concentration of 33 μM, its anti-inflammatory effect is comparable to that of the clinically proven positive drug dexamethasone, and in some aspects, it is even superior. This invention not only provides a new lead compound for the development of anti-inflammatory drugs but also opens up new directions for developing new drugs from the unique microbial resource of nematode-preying fungi.

The invention relates to the technical field of traditional Chinese medicine extraction and separation, in particular to an extraction and separation method of a pyridine alkaloid compound in purslane and application of the pyridine alkaloid compound. The molecular formula of the pyridine alkaloid compound is C6H8N2O, and the pyridine alkaloid compound is named as 6-metaxyridin-3-amine. According to the method, ethyl alcohol reflux extraction, ODS column, Sephadex LH-20, a high performance liquid chromatograph and the like are adopted for separation, purification and preparation, 6-methoxyridin-3-amine is successfully extracted and separated, the method is easy to operate, the operation method is simple, convenient and rapid, ethyl alcohol and methyl alcohol are mainly adopted for extraction in the extraction and separation process, the technological method is environmentally friendly, and the method is suitable for industrial production. The purity of the compound separated by the method is higher than 99%, and research shows that the compound has an anti-inflammatory effect, so that the pyridine alkaloid compound and the salt and the derivative thereof can be used as synthesis primers of other compounds and raw materials for new drug development and pharmacological activity research, and can also be used for preparing anti-inflammatory drugs.

The invention belongs to the field of new traditional Chinese medicine development, and particularly relates to a traditional Chinese medicine composition composed of herba epimedii, uncaria, radix scrophulariae, rhizoma alismatis and radix cyathulae, an extraction method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition to treatment of blood pressure circadian rhythm disorder of hypertension. The pharmaceutical composition comprises the following raw material medicines: herba epimedii, uncaria, radix scrophulariae, rhizoma alismatis and radix cyathulae. The traditional Chinese medicine composition provided by the invention is suitable for hypertension disease blood pressure circadian rhythm disorder. According to the pathogenesis characteristics of hypertension, the invention provides the novel traditional Chinese medicine composition for treating blood pressure circadian rhythm disorder of hypertension and the preparation method thereof, and the compatibility effect of mutual promotion and mutual assistance is exerted according to the compatibility principle of monarch, minister, assistant and guide of traditional Chinese herbal medicines. The traditional Chinese medicine composition disclosed by the invention can effectively reduce systolic pressure and diastolic pressure of a hypertensive patient in 24 hours and control morning and night hypertension, and is high in safety. The traditional Chinese medicine composition provides a theoretical and clinical basis and a novel prescription strategy for clinically preventing and treating blood pressure circadian rhythm disorder of hypertension in traditional Chinese medicine.

The invention provides a method for evaluating the efficacy of treating climacteric hectic fever, which comprises the following steps: collecting literature data of climacteric hectic fever according to a predetermined standard, constructing a data set, and evaluating the quality of the data set; constructing a pharmacodynamic model based on a quality evaluation result and a predetermined curative effect index in the data set, and evaluating the constructed pharmacodynamic model; and performing quantitative analysis processing on time effect distribution and covariable influence factors of drug treatment based on the evaluated pharmacodynamic model so as to simulate and predict result data of drug efficacy parameters and covariable influence degrees of drugs to evaluate time-effect characteristics of drug treatment. The evaluation method can assist in determining the optimal clinical medication treatment strategy of the medicine, and can also provide a diachronic standard curative effect scale reference for the development of a new medicine for treating female climacteric hectic fever.

The present application relates to the application of ocanin in the preparation of anti-tumor drugs, and the ocanin is used in the anti-tumor drugs alone or in combination with 5-fluorouracil, and the concentration of the ocanin used in the preparation of anti-intestinal cancer drugs is 20-500 uMol. It is found that the ocanin can inhibit the growth of intestinal cancer cells in vivo and in vitro, and the naked mice have good tolerance to the natural compound. The ocanin has better anti-intestinal cancer effect than other extracts of goldeneye and devil's needle, and has better anti-cancer effect and smaller toxicity than the current conventional intestinal cancer drug 5-fluorouracil. Therefore, the ocanin can be developed into a new anti-cancer drug.

The invention discloses a luminescent cell for rapidly detecting drug allergy and / or anaphylactoid reaction as well as a construction method and application of the luminescent cell, and relates to the technical field of biology. The construction method comprises the following steps: transforming myeloid related cells by using a recombinant vector containing a marker gene and an HHEXA gene promoter to obtain recombinant cells; the recombinant cell is the luminescent cell. According to the invention, the HHEXA gene promoter and the marker gene are recombined and then transferred into myeloid related cells, and the occurrence of the allergy or anaphylactoid reaction can be intuitively reflected through a marker signal by utilizing the specific activation characteristic of the HHEXA gene in the allergy / anaphylactoid reaction. The luminescent cell has good stability, is suitable for multiple scenes such as drug allergy, anaphylactoid risk assessment, environmental sample analysis and the like, provides an efficient, sensitive and convenient technical tool for clinical rapid diagnosis, new drug research and development and scientific research and exploration, and can significantly reduce the detection cost and the operation threshold.

The invention discloses a traditional Chinese medicine composition for resisting ovarian cancer and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine is characterized by being prepared from the following raw materials in parts by weight: 30 parts of astragalus membranaceus, 9 parts of dandelion, 9 parts of cyrtomium fortunei, 9 parts of sanguisorba officinalis, 9 parts of pericarpium citri reticulatae, 9 parts of honeysuckle, 9 parts of ginseng, 9 parts of cirsium japonicum, 9 parts of herba cepbalanoplosis segeti, 15 parts of longan aril, 15 parts of radix rehmanniae, 15 parts of eucommia ulmoides and 6 parts of pseudo-ginseng. The invention not only proves the phenotypic effects of the tonifying and cancer eliminating decoction for inhibiting the proliferation and migration of ovarian cancer cells and inducing apoptosis, but also finds that the effect of the tonifying and cancer eliminating decoction is closely related to the activation of inhibiting a PI3K-AKT signal channel for the first time, the scientific connotation of the tonifying and cancer eliminating decoction is clarified from the molecular level, and an important preclinical research foundation is laid for developing the tonifying and cancer eliminating decoction into a modern new traditional Chinese medicine for resisting ovarian cancer.

The invention belongs to the technical field of medicines, and discloses application of a compound M1 shown as a formula (I) and pharmacodynamically acceptable salt thereof in preparation of medicines for preventing, relieving and / or treating autoimmune demyelination diseases. On a mouse experimental autoimmune encephalomyelitis model, the compound M1 shows a good treatment effect, can effectively prevent and treat pathological changes and disease progression of diseases, relieve the severity of the diseases and inhibit LPS-stimulated microglial BV2 cells from releasing inflammatory mediators, and provides a new drug and a new structure for clinical treatment.

The application relates to a method for constructing a congenital pure red cell anemia zebra fish model, which comprises the following steps: performing directional mutation on a bysl gene in a wild-type zebra fish embryo to obtain F0 generation zebra fish; mating the F0 generation zebra fish with wild-type zebra fish to screen positive heterozygote F1 generation zebra fish from born zebra fish; mating the positive heterozygote F1 generation zebra fish with wild-type zebra fish to screen positive heterozygote F2 generation zebra fish from born zebra fish; and mating the positive heterozygote F2 generation zebra fish to screen positive homozygote zebra fish from born zebra fish as a congenital pure red cell anemia zebra fish model. The model can simulate the symptoms of congenital pure red cell anemia, and can be used for mechanism research, drug evaluation and new drug screening of the disease.